Churg-Strauss Syndrome

Churg-Strauss Syndrome, clinically known as Eosinophilic Granulomatosis with Polyangiitis (EGPA), is a rare systemic necrotizing vasculitis characterized by eosinophil-rich inflammation involving multiple organ systems, most notably the lungs, skin, and peripheral nerves. It typically evolves through three phases: prodromal (allergic), eosinophilic, and vasculitic.

The exact cause remains idiopathic. It is thought to involve a complex interplay between environmental triggers (e.g., allergens, medications like leukotriene receptor antagonists) and an underlying genetic predisposition. It is not strictly hereditary but may involve specific HLA-DRB4 gene polymorphisms.

EGPA is characterized by Th2-mediated immune responses leading to tissue infiltration by eosinophils. Cytokines such as IL-5 stimulate eosinophil survival and activation, resulting in degranulation and release of cytotoxic proteins (e.g., major basic protein), which damage endothelial cells, leading to systemic vasculitis and granuloma formation.

EGPA is rare, with an incidence of 0.5–6.8 per million per year. The average age of onset is 38–54 years, with a slight male predominance, though it can occur at any age.

• History of severe adult-onset asthma
• Chronic rhinosinusitis and nasal polyposis
• Allergic rhinitis
• Certain medications (e.g., montelukast)

A. Early Symptoms

• Persistent asthma


• Allergic rhinitis


• Nasal polyps B. Common Symptoms


• Fatigue


• Fever


• Night sweats


• Weight loss


• Myalgia and arthralgia C. Advanced Symptoms


• Mononeuritis multiplex (foot drop/wrist drop)


• Purpura or skin nodules


• Abdominal pain


• Diarrhea D. Emergency Symptoms


• Sudden shortness of breath (hemoptysis)


• Chest pain


• Acute neurological deficits (stroke symptoms)


• Severe gastrointestinal bleeding

• Wheezing on auscultation
• Palpable purpura or subcutaneous nodules
• Decreased sensation/strength in distal limbs (neuropathy)
• Sinus tenderness
• Hypertension (if renal involvement exists)

A. Clinical Assessment: ACR criteria (asthma, eosinophilia, neuropathy, pulmonary infiltrates, sinus abnormality, extravascular eosinophils).
B. Laboratory Testing: CBC for eosinophil count, ANCA status.
C. Imaging Studies: Chest X-ray/CT for infiltrates.
D. Functional Tests: Pulmonary function tests (PFTs).
E. Biopsy Findings: Eosinophilic infiltration, extravascular granulomas, necrotizing vasculitis.
F. Genetic Testing: Not standard.
G. Differential Diagnosis: Hypereosinophilic syndrome, GPA, PAN, drug-induced vasculitis.

Peripheral Eosinophil Count
Type: Blood Test
Purpose: Assess inflammatory status
Expected Findings: >10% of total WBC count
Interpretation: Significant marker for eosinophilic activity ANCA (Anti-neutrophil cytoplasmic antibodies)
Type: Blood Test
Purpose: Diagnostic classification
Expected Findings: Positive in ~40% of cases (usually MPO-ANCA)
Interpretation: Suggests specific vasculitic subtype

Chest CT
Purpose: Detect lung involvement
Typical Findings: Peripheral opacities, ground-glass attenuation
Clinical Importance: Identifies degree of pulmonary vasculitis

• Granulomatosis with Polyangiitis (GPA): Usually lacks severe asthma/eosinophilia.
• Hypereosinophilic Syndrome (HES): Lacks classic vasculitis/granulomas.
• Polyarteritis Nodosa (PAN): Lacks pulmonary involvement and eosinophilia.

• Chronic kidney disease
• Congestive heart failure (eosinophilic myocarditis)
• Permanent peripheral nerve damage
• Respiratory failure

A. Lifestyle Modifications: Allergen avoidance, smoking cessation.
B. Preventive Measures: Vaccination against influenza/pneumonia.
C. Medical Treatment

• Corticosteroids (Prednisone): Primary immunosuppression.


• Cyclophosphamide: Severe disease induction.


• Rituximab/Mepolizumab: Adjunctive or steroid-sparing therapy (IL-5 inhibition). D. Surgical Treatment: Sinus surgery for polyposis.

Good if diagnosed early; mortality is usually due to cardiovascular disease or organ failure. Relapses are common and require long-term monitoring.

No primary prevention. Secondary prevention involves aggressive control of asthma and maintenance immunosuppression.

The following homeopathic remedies have been historically indicated for symptoms associated with Churg-Strauss Syndrome. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Churg-Strauss Syndrome.